176 related articles for article (PubMed ID: 16198987)
21. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
22. [The role of imatinib in the treatment of acute lymphoid leukemias].
Poros A; Lovas N
Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.
Nakasone H; Kanda Y; Takasaki H; Nakaseko C; Sakura T; Fujisawa S; Yokota A; Yano S; Usuki K; Maruta A; Abe D; Hoshino T; Takahashi S; Kanamori H; Okamoto S;
Leukemia; 2010 Jun; 24(6):1236-9. PubMed ID: 20428195
[No Abstract] [Full Text] [Related]
24. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
Tiribelli M; Marin L; Calistri E; Geromin A; Damiani D; Fanin R
Bone Marrow Transplant; 2004 Nov; 34(9):827-8. PubMed ID: 15334052
[No Abstract] [Full Text] [Related]
25. [Current treatment of philadelphia chromosome-positive acute lymphoblastic leukemia].
Sugiura I
Rinsho Ketsueki; 2014 Oct; 55(10):1972-80. PubMed ID: 25297762
[No Abstract] [Full Text] [Related]
26. Chronic myelogenous leukemia.
Mauro MJ; Druker BJ
Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
[TBL] [Abstract][Full Text] [Related]
27. Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Gopcsa L; Barta A; Bányai A; Dolgos J; Halm G; Pálóczi K
Pathol Oncol Res; 2003; 9(2):131-3. PubMed ID: 12858220
[TBL] [Abstract][Full Text] [Related]
28. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib.
Pavlu J; Czepulkowski B; Kaczmarski R; Jan-Mohamed R
Lancet Oncol; 2005 Feb; 6(2):128. PubMed ID: 15683824
[No Abstract] [Full Text] [Related]
29. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.
Cherrier-De Wilde S; Rack K; Vannuffel P; Delannoy A; Hagemeijer A
Leukemia; 2003 Oct; 17(10):2046-8. PubMed ID: 14513056
[No Abstract] [Full Text] [Related]
30. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Wang Y; Wu D; Sun A; Jin Z; Qiu H; Miao M; Tang X; Fu Z
Int J Hematol; 2008 Mar; 87(2):167-171. PubMed ID: 18288566
[TBL] [Abstract][Full Text] [Related]
31. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
Yoshimitsu M; Fujiwara H; Ozaki A; Hamada H; Matsushita K; Arima N; Tei C
Int J Hematol; 2008 Oct; 88(3):331-335. PubMed ID: 18696183
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
33. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
Anderlini P; Sheth S; Hicks K; Ippoliti C; Giralt S; Champlin RE
Biol Blood Marrow Transplant; 2004 Dec; 10(12):883-4. PubMed ID: 15570257
[No Abstract] [Full Text] [Related]
34. Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia.
Yamada K; Yasui M; Kondo O; Sato M; Sawada A; Kawa K; Inoue M
Pediatr Blood Cancer; 2013 Aug; 60(8):E60-2. PubMed ID: 23468187
[TBL] [Abstract][Full Text] [Related]
35. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
[TBL] [Abstract][Full Text] [Related]
36. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant.
Martin SE; DellaValla J
Leukemia; 2005 Jun; 19(6):1095-6. PubMed ID: 15789065
[No Abstract] [Full Text] [Related]
37. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N; Ottmann OG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Gutiérrez-Aguirre H; García-Rodríguez F; Cantú-Rodríguez O; González-Llano O; Jaime-Pérez J; Gómez-Almaguer D
Clin Adv Hematol Oncol; 2011 Nov; 9(11):875-8. PubMed ID: 22252621
[No Abstract] [Full Text] [Related]
40. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
